Replies to post #319233 on Bioelectronics Corp (BIEL)

[JNdouble1]

would you want to give me exclusivity on your product when I’ve not met my quota for the OEM you supply

No, of course not, but that is a problem. The OEM re-sellers are not performing. The OEM business model is failing. This should be admitted, so that we may move on.

Should RRx given the above, reach critical mass adoption or even Standard of Care,

I think you are putting the cart before the horse; we are light years away from critical mass, and Standard of Care isn't even on the radar. The product has to be used, doctors and hospitals, and insurance companies have to see concrete evidence of its benefits. All the nice language, and turns of phrase notwithstanding, you are not saying anything that has a legitimate basis in reality.

what fruit, if any, is borne via the new “things” in process, as has been shared by others on this forum

There hasn't been much of anything shared on this forum of value regarding new things in process. Nonsense about former employees secretly working behind the scenes. Links to a myriad of online outlets and new distributors selling the device overseas none of which results in increasing revenues. It's tin foil hat level discussion here most of the time as far as I am reading. Yes there is a new law regarding medicaid/medicare reimbursement for non-opioid treatments. That deserves it's own discussion, but suffice it to say, I think potential the benefits to BIEL are being exaggerated.

There is no path out of the darkness of the proverbial tunnel that can be entertained if one’s flashlight is pointed backwards instead of forward.

And it doesn't make any difference what direction your flashlight is facing if the light is off.

[JNdouble1]

Ok, let's talk about the NoPain act...

I've been doing some research, trying to get my head around what the real opportunity looks like. I want to use actual numbers and data, not just hope and optimism.

So, if you will indulge mem, I want your opinion on a few things that are relevant to the discussion:

• What percentage of opioid prescriptions will be diverted due to the act in it's first year?
  
• Of all the options available, what percentage of diverted prescriptions will go to BIEL?
  
• What will BIEL's margins be, $/device, or % of reimbursement?
  
• What is BIEL's profit margin?
  

Here are some important points to consider:

• The act only applies to Hospital Out Patient Department, and Ambulatory Surgery Centers, GPs and family doctors aren't part of the program
  
• The act stipulates that the reimbursements must be budget neutral, either cuts in other areas of care, which no one will like, or negotiated low prices for non-opioid therapies, remember that opioids were the cheap option already
  
• Charging higher prices than the "generic" or OTC version will likely be point of discussion
  
• The rest will come in the discussion
  

[art2426]

I have said it for years, check my posts. Absolutely amateur and STUPID to give an exclusive contractual sales agreement without including a minimum sales requirement that must be met. And if not met in a agreed time frame, contract becomes null and void. That is common sense.

Sad that this company was selling more product before those OEM deals.